Hypertension with renal impairment: influence of intensive therapy.
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D003404:Creatinine / Q000378:metabolism; D003981:Diazoxide / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007511:Ischemia / Q000150:complications; D007668:Kidney / Q000098:blood supply; D007674:Kidney Diseases / Q000150:complications*; D007677:Kidney Function Tests; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010211:Papilledema / Q000150:complications; D007690:Polycystic Kidney Diseases / Q000150:complications; D011433:Propranolol / Q000627:therapeutic use; D011704:Pyelonephritis / Q000150:complications; D014508:Urea / Q000097:blood
D008750:Methyldopa; D014508:Urea; D011433:Propranolol; D003404:Creatinine; D003981:Diazoxide